Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis

Edward H. Giannini, Norman Todd Ilowite, Daniel J. Lovell, Carol A. Wallace, C. Egla Rabinovich, Andreas Reiff, Gloria Higgins, Beth Gottlieb, Yun Chon, Nan Zhang, Scott W. Baumgartner

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective To evaluate the effects of long-term etanercept treatment, with or without methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA). Methods We conducted a 3-year, open-label, nonrandomized registry of 594 patients with polyarticular or systemic JIA treated with etanercept only, etanercept plus methotrexate, or methotrexate only. Height, weight, and body mass index (BMI) were assessed at baseline and at years 1, 2, and 3, using percentiles derived from US Centers for Disease Control and Prevention standardized growth charts. Results Statistically significant increases in the mean height percentiles from baseline were observed in etanercept-treated patients at year 3 (4.8 percentile points) and in patients treated with etanercept plus methotrexate at years 1, 2, and 3 (2.4, 3.3, and 5.6 percentile points, respectively). Statistically significant increases from baseline in the mean weight percentiles were observed at years 1, 2, and 3 in both the etanercept group (7.4, 10.0, and 13.0 percentile points) and the etanercept-plus-methotrexate group (2.9, 6.9, and 8.4 percentile points, respectively). Statistically significant increases from baseline in the mean BMI percentiles were observed in both the etanercept group (range 9.6-13.8 percentile points) and the etanercept-plus-methotrexate group (range 2.1-5.2 percentile points). The mean height, weight, and BMI percentiles did not change significantly in patients in the methotrexate-only group. Conclusion Etanercept treatment, with or without methotrexate, may contribute to the restoration of normal growth in children with JIA.

Original languageEnglish (US)
Pages (from-to)3259-3264
Number of pages6
JournalArthritis and Rheumatism
Volume62
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Juvenile Arthritis
Methotrexate
Growth
Therapeutics
Body Mass Index
Weights and Measures
Etanercept
Growth Charts
Centers for Disease Control and Prevention (U.S.)
Registries

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Giannini, E. H., Ilowite, N. T., Lovell, D. J., Wallace, C. A., Rabinovich, C. E., Reiff, A., ... Baumgartner, S. W. (2010). Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis and Rheumatism, 62(11), 3259-3264. https://doi.org/10.1002/art.27682

Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. / Giannini, Edward H.; Ilowite, Norman Todd; Lovell, Daniel J.; Wallace, Carol A.; Rabinovich, C. Egla; Reiff, Andreas; Higgins, Gloria; Gottlieb, Beth; Chon, Yun; Zhang, Nan; Baumgartner, Scott W.

In: Arthritis and Rheumatism, Vol. 62, No. 11, 11.2010, p. 3259-3264.

Research output: Contribution to journalArticle

Giannini, EH, Ilowite, NT, Lovell, DJ, Wallace, CA, Rabinovich, CE, Reiff, A, Higgins, G, Gottlieb, B, Chon, Y, Zhang, N & Baumgartner, SW 2010, 'Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis', Arthritis and Rheumatism, vol. 62, no. 11, pp. 3259-3264. https://doi.org/10.1002/art.27682
Giannini, Edward H. ; Ilowite, Norman Todd ; Lovell, Daniel J. ; Wallace, Carol A. ; Rabinovich, C. Egla ; Reiff, Andreas ; Higgins, Gloria ; Gottlieb, Beth ; Chon, Yun ; Zhang, Nan ; Baumgartner, Scott W. / Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. In: Arthritis and Rheumatism. 2010 ; Vol. 62, No. 11. pp. 3259-3264.
@article{62039af13339454ebe62ec74367c1479,
title = "Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis",
abstract = "Objective To evaluate the effects of long-term etanercept treatment, with or without methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA). Methods We conducted a 3-year, open-label, nonrandomized registry of 594 patients with polyarticular or systemic JIA treated with etanercept only, etanercept plus methotrexate, or methotrexate only. Height, weight, and body mass index (BMI) were assessed at baseline and at years 1, 2, and 3, using percentiles derived from US Centers for Disease Control and Prevention standardized growth charts. Results Statistically significant increases in the mean height percentiles from baseline were observed in etanercept-treated patients at year 3 (4.8 percentile points) and in patients treated with etanercept plus methotrexate at years 1, 2, and 3 (2.4, 3.3, and 5.6 percentile points, respectively). Statistically significant increases from baseline in the mean weight percentiles were observed at years 1, 2, and 3 in both the etanercept group (7.4, 10.0, and 13.0 percentile points) and the etanercept-plus-methotrexate group (2.9, 6.9, and 8.4 percentile points, respectively). Statistically significant increases from baseline in the mean BMI percentiles were observed in both the etanercept group (range 9.6-13.8 percentile points) and the etanercept-plus-methotrexate group (range 2.1-5.2 percentile points). The mean height, weight, and BMI percentiles did not change significantly in patients in the methotrexate-only group. Conclusion Etanercept treatment, with or without methotrexate, may contribute to the restoration of normal growth in children with JIA.",
author = "Giannini, {Edward H.} and Ilowite, {Norman Todd} and Lovell, {Daniel J.} and Wallace, {Carol A.} and Rabinovich, {C. Egla} and Andreas Reiff and Gloria Higgins and Beth Gottlieb and Yun Chon and Nan Zhang and Baumgartner, {Scott W.}",
year = "2010",
month = "11",
doi = "10.1002/art.27682",
language = "English (US)",
volume = "62",
pages = "3259--3264",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis

AU - Giannini, Edward H.

AU - Ilowite, Norman Todd

AU - Lovell, Daniel J.

AU - Wallace, Carol A.

AU - Rabinovich, C. Egla

AU - Reiff, Andreas

AU - Higgins, Gloria

AU - Gottlieb, Beth

AU - Chon, Yun

AU - Zhang, Nan

AU - Baumgartner, Scott W.

PY - 2010/11

Y1 - 2010/11

N2 - Objective To evaluate the effects of long-term etanercept treatment, with or without methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA). Methods We conducted a 3-year, open-label, nonrandomized registry of 594 patients with polyarticular or systemic JIA treated with etanercept only, etanercept plus methotrexate, or methotrexate only. Height, weight, and body mass index (BMI) were assessed at baseline and at years 1, 2, and 3, using percentiles derived from US Centers for Disease Control and Prevention standardized growth charts. Results Statistically significant increases in the mean height percentiles from baseline were observed in etanercept-treated patients at year 3 (4.8 percentile points) and in patients treated with etanercept plus methotrexate at years 1, 2, and 3 (2.4, 3.3, and 5.6 percentile points, respectively). Statistically significant increases from baseline in the mean weight percentiles were observed at years 1, 2, and 3 in both the etanercept group (7.4, 10.0, and 13.0 percentile points) and the etanercept-plus-methotrexate group (2.9, 6.9, and 8.4 percentile points, respectively). Statistically significant increases from baseline in the mean BMI percentiles were observed in both the etanercept group (range 9.6-13.8 percentile points) and the etanercept-plus-methotrexate group (range 2.1-5.2 percentile points). The mean height, weight, and BMI percentiles did not change significantly in patients in the methotrexate-only group. Conclusion Etanercept treatment, with or without methotrexate, may contribute to the restoration of normal growth in children with JIA.

AB - Objective To evaluate the effects of long-term etanercept treatment, with or without methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA). Methods We conducted a 3-year, open-label, nonrandomized registry of 594 patients with polyarticular or systemic JIA treated with etanercept only, etanercept plus methotrexate, or methotrexate only. Height, weight, and body mass index (BMI) were assessed at baseline and at years 1, 2, and 3, using percentiles derived from US Centers for Disease Control and Prevention standardized growth charts. Results Statistically significant increases in the mean height percentiles from baseline were observed in etanercept-treated patients at year 3 (4.8 percentile points) and in patients treated with etanercept plus methotrexate at years 1, 2, and 3 (2.4, 3.3, and 5.6 percentile points, respectively). Statistically significant increases from baseline in the mean weight percentiles were observed at years 1, 2, and 3 in both the etanercept group (7.4, 10.0, and 13.0 percentile points) and the etanercept-plus-methotrexate group (2.9, 6.9, and 8.4 percentile points, respectively). Statistically significant increases from baseline in the mean BMI percentiles were observed in both the etanercept group (range 9.6-13.8 percentile points) and the etanercept-plus-methotrexate group (range 2.1-5.2 percentile points). The mean height, weight, and BMI percentiles did not change significantly in patients in the methotrexate-only group. Conclusion Etanercept treatment, with or without methotrexate, may contribute to the restoration of normal growth in children with JIA.

UR - http://www.scopus.com/inward/record.url?scp=78249250295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249250295&partnerID=8YFLogxK

U2 - 10.1002/art.27682

DO - 10.1002/art.27682

M3 - Article

C2 - 20669280

AN - SCOPUS:78249250295

VL - 62

SP - 3259

EP - 3264

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 11

ER -